amuvatinib

{
  "id": "MLC-T-ONC-000479",
  "term": "amuvatinib",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A substance being studied in the treatment of some types of cancer. It may block certain proteins involved in cancer cell growth and DNA repair. Blocking these proteins may make cancer cells more sensitive to anticancer drugs and radiation therapy. Amuvatinib is a type of tyrosine kinase inhibitor. Also called MP470.",
    "An orally bioavailable synthetic carbothioamide with potential antineoplastic activity. Multitargeted receptor tyrosine kinase inhibitor MP470 binds to mutant forms of the stem cell factor receptor (c-Kit; SCFR), inhibiting clinically relevant mutants of this receptor tyrosine kinase that may be associated with resistance to therapy. In addition, MP470 inhibits activities of other receptor tyrosine kinases, such as c-Met, Ret oncoprotein, and mutant forms of Flt3 and PDGFR alpha, which are frequently dysregulated in variety of tumors. This agent also suppresses the induction of DNA repair protein Rad51, thereby potentiating the activities of DNA damage-inducing agents. Mutant forms of c-Kit are often associated with tumor chemoresistance."
  ],
  "synonyms": [
    "MP470",
    "receptor tyrosine kinase inhibitor MP470"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/amuvatinib/"
}